Teva Pharmaceutical Industries Limited Stock News

Teva Pharmaceutical's divestments have been many in recent years, and the company presents a different set-up than in the past. In about 5 years Teva Pharmaceutical has reduced its net debt by $14 bil

Teva, Dr. Reddy's and Sol-Gel have been highlighted in this Industry Outlook article.

The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.

The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares climbed 199.6% to close at $7.64 on Wednesday after the company announced it plans to explore the potential development of a novel monkeypox vac

Embark Technology, Inc. (NASDAQ: EMBK) fell 25.1% to $12.40. Embark Technology reported the completion of reverse stock split. Blueprint Medicines Corporation (NASDAQ: BPMC) fell 22.5% to $53.11 af

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus

Bausch (BHC) will appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patent decision for one of its key drugs Xifaxan.

Teva Pharmaceutical's revenue was $3,786 million in Q2 2022, up 3.4% QoQ. See why we believe there is huge potential for TEVA stock with target price of $25.

Teva Pharmaceutical's revenue was $3,786 million in Q2 2022, up 3.4% QoQ. The company's total debt continues to decline quarter on quarter and stands at $22,453 million at the end of Q2 2022.

Bank of America finds its inner bull with the generics producer.

Bank of America finds its inner bull with the generics producer.

Following Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) opioid settlement, the Tel Aviv-Yafo, Israel-based company seems to be making “material progress” in clearing its litigation overhang

Upgrades For 8x8 Inc (NYSE:EGHT), Craig-Hallum upgraded the previous rating of Hold to Buy. In the first quarter, 8x8 showed an EPS of $0.09, compared to $0.01 from the year-ago quarter. At the moment

Stifel cut the price target for Twilio Inc. (NYSE: TWLO) from $200 to $90. Twilio shares fell 9.6% to $88.75 in pre-market trading. B of A Securities boosted the price target on Teva Pharmaceutical